vs

Side-by-side financial comparison of PHIBRO ANIMAL HEALTH CORP (PAHC) and Perion Network Ltd. (PERI). Click either name above to swap in a different company.

PHIBRO ANIMAL HEALTH CORP is the larger business by last-quarter revenue ($373.9M vs $368.7M, roughly 1.0× Perion Network Ltd.). PHIBRO ANIMAL HEALTH CORP runs the higher net margin — 7.3% vs 2.1%, a 5.3% gap on every dollar of revenue. PHIBRO ANIMAL HEALTH CORP produced more free cash flow last quarter ($8.3M vs $-2.9M). Over the past eight quarters, PHIBRO ANIMAL HEALTH CORP's revenue compounded faster (19.2% CAGR vs 16.4%).

Phibro Animal Health Corporation is an American animal health and mineral nutrition company. Its products include antibacterials, anticoccidials, anthelmintics, as well as animal nutrition and vaccines for livestock. The company operates through three segments Mineral Nutrition, Performance Materials, and Animal Health, from which most of its revenue is derived. The company operates in the United States, Latin America, Canada, Europe, Middle East, Africa, and Asia-Pacific. It is incorporated ...

Perion Network Ltd. is a publicly traded advertising technology company that provides digital advertising technology solutions to advertisers, agencies, retailers, and publishers. Its core offerings are delivered through Perion One, a unified omnichannel advertising platform designed to support campaign planning, activation, optimisation, and measurement across channels and verticals including connected television (CTV), digital out-of-home (DOOH), display, video advertising, as well as retai...

PAHC vs PERI — Head-to-Head

Bigger by revenue
PAHC
PAHC
1.0× larger
PAHC
$373.9M
$368.7M
PERI
Higher net margin
PAHC
PAHC
5.3% more per $
PAHC
7.3%
2.1%
PERI
More free cash flow
PAHC
PAHC
$11.1M more FCF
PAHC
$8.3M
$-2.9M
PERI
Faster 2-yr revenue CAGR
PAHC
PAHC
Annualised
PAHC
19.2%
16.4%
PERI

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
PAHC
PAHC
PERI
PERI
Revenue
$373.9M
$368.7M
Net Profit
$27.5M
$7.7M
Gross Margin
35.5%
Operating Margin
13.5%
2.0%
Net Margin
7.3%
2.1%
Revenue YoY
20.9%
Net Profit YoY
762.1%
EPS (diluted)
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PAHC
PAHC
PERI
PERI
Q4 25
$373.9M
Q3 25
$363.9M
$368.7M
Q2 25
$378.7M
$266.5M
Q1 25
$347.8M
$157.8M
Q4 24
$309.3M
Q3 24
$260.4M
$508.9M
Q2 24
$273.2M
$323.6M
Q1 24
$263.2M
$145.2M
Net Profit
PAHC
PAHC
PERI
PERI
Q4 25
$27.5M
Q3 25
$26.5M
$7.7M
Q2 25
$17.2M
$5.6M
Q1 25
$20.9M
$11.8M
Q4 24
$3.2M
Q3 24
$7.0M
$78.0M
Q2 24
$752.0K
$45.2M
Q1 24
$8.4M
$23.8M
Gross Margin
PAHC
PAHC
PERI
PERI
Q4 25
35.5%
Q3 25
32.9%
Q2 25
29.0%
Q1 25
30.1%
Q4 24
32.9%
Q3 24
32.1%
Q2 24
31.9%
Q1 24
30.2%
Operating Margin
PAHC
PAHC
PERI
PERI
Q4 25
13.5%
Q3 25
14.1%
2.0%
Q2 25
8.9%
-1.7%
Q1 25
9.6%
5.4%
Q4 24
8.3%
Q3 24
6.8%
15.1%
Q2 24
6.7%
13.7%
Q1 24
7.6%
16.9%
Net Margin
PAHC
PAHC
PERI
PERI
Q4 25
7.3%
Q3 25
7.3%
2.1%
Q2 25
4.5%
2.1%
Q1 25
6.0%
7.5%
Q4 24
1.0%
Q3 24
2.7%
15.3%
Q2 24
0.3%
14.0%
Q1 24
3.2%
16.4%
EPS (diluted)
PAHC
PAHC
PERI
PERI
Q4 25
$0.67
Q3 25
$0.65
Q2 25
$0.43
Q1 25
$0.51
Q4 24
$0.08
Q3 24
$0.17
Q2 24
$0.02
Q1 24
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PAHC
PAHC
PERI
PERI
Cash + ST InvestmentsLiquidity on hand
$74.5M
$156.2M
Total DebtLower is stronger
$624.2M
Stockholders' EquityBook value
$332.4M
$722.9M
Total Assets
$1.4B
$915.5M
Debt / EquityLower = less leverage
1.88×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PAHC
PAHC
PERI
PERI
Q4 25
$74.5M
Q3 25
$85.3M
$156.2M
Q2 25
$77.0M
$156.2M
Q1 25
$70.4M
$156.2M
Q4 24
$67.1M
Q3 24
$89.8M
$187.6M
Q2 24
$114.6M
$187.6M
Q1 24
$98.7M
$187.6M
Total Debt
PAHC
PAHC
PERI
PERI
Q4 25
$624.2M
Q3 25
$628.0M
Q2 25
$631.7M
Q1 25
$635.4M
Q4 24
$639.1M
Q3 24
$295.2M
Q2 24
$312.1M
Q1 24
Stockholders' Equity
PAHC
PAHC
PERI
PERI
Q4 25
$332.4M
Q3 25
$311.7M
$722.9M
Q2 25
$285.7M
$722.9M
Q1 25
$266.0M
$722.9M
Q4 24
$246.8M
Q3 24
$258.5M
$718.1M
Q2 24
$256.6M
$718.1M
Q1 24
$270.1M
$718.1M
Total Assets
PAHC
PAHC
PERI
PERI
Q4 25
$1.4B
Q3 25
$1.4B
$915.5M
Q2 25
$1.4B
$915.5M
Q1 25
$1.3B
$915.5M
Q4 24
$1.3B
Q3 24
$966.3M
$1.1B
Q2 24
$982.2M
$1.1B
Q1 24
$979.0M
$1.1B
Debt / Equity
PAHC
PAHC
PERI
PERI
Q4 25
1.88×
Q3 25
2.01×
Q2 25
2.21×
Q1 25
2.39×
Q4 24
2.59×
Q3 24
1.14×
Q2 24
1.22×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PAHC
PAHC
PERI
PERI
Operating Cash FlowLast quarter
$19.4M
$2.6M
Free Cash FlowOCF − Capex
$8.3M
$-2.9M
FCF MarginFCF / Revenue
2.2%
-0.8%
Capex IntensityCapex / Revenue
3.0%
1.5%
Cash ConversionOCF / Net Profit
0.70×
0.34×
TTM Free Cash FlowTrailing 4 quarters
$47.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PAHC
PAHC
PERI
PERI
Q4 25
$19.4M
Q3 25
$9.3M
$2.6M
Q2 25
$21.3M
Q1 25
$43.2M
Q4 24
$3.1M
Q3 24
$12.6M
$105.2M
Q2 24
$28.4M
Q1 24
$11.4M
$17.8M
Free Cash Flow
PAHC
PAHC
PERI
PERI
Q4 25
$8.3M
Q3 25
$-4.5M
$-2.9M
Q2 25
$8.1M
Q1 25
$35.4M
Q4 24
$-4.7M
Q3 24
$3.0M
$104.7M
Q2 24
$15.4M
Q1 24
$1.7M
$17.6M
FCF Margin
PAHC
PAHC
PERI
PERI
Q4 25
2.2%
Q3 25
-1.2%
-0.8%
Q2 25
2.1%
Q1 25
10.2%
Q4 24
-1.5%
Q3 24
1.2%
20.6%
Q2 24
5.6%
Q1 24
0.6%
12.2%
Capex Intensity
PAHC
PAHC
PERI
PERI
Q4 25
3.0%
Q3 25
3.8%
1.5%
Q2 25
3.5%
Q1 25
2.2%
Q4 24
2.5%
Q3 24
3.7%
0.1%
Q2 24
4.8%
Q1 24
3.7%
0.1%
Cash Conversion
PAHC
PAHC
PERI
PERI
Q4 25
0.70×
Q3 25
0.35×
0.34×
Q2 25
1.24×
Q1 25
2.07×
Q4 24
0.97×
Q3 24
1.81×
1.35×
Q2 24
37.80×
Q1 24
1.36×
0.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PAHC
PAHC

Medicated Feed Additives And Others$202.1M54%
Mineral Nutrition$68.9M18%
Nutritional Specialties$50.2M13%
Vaccines$37.6M10%
Performance Products$15.0M4%

PERI
PERI

Advertising Solutions$231.4M63%
Search Advertising$137.3M37%

Related Comparisons